An All-Oral Revumenib Combination Achieves 100% ORR Patients with R/R AML
Results from the phase 1/2 SAVE trial demonstrated an improved objective response rate when revumenib was added to decitabine/cedazuridine, and venetoclax for patients with relapsed/refractory acute myeloid leukemia.
Pembrolizumab/Olaparib Did Not Improve Survival in Locally Advanced or Metastatic TNBC
Maintenance pembrolizumab plus olaparib did not improve progression-free or overall survival in patients with locally recurrent inoperable or metastatic triple-negative breast cancer.
Superior Survival and Time to Treatment Are Hallmarks of Early Adoption of ctDNA
The early adoption of ctDNA into the clinical workflow improves time to treatment, survival, and monitoring for patients undergoing molecular-based therapy.
Mirvetuximab Soravtansine Results from MIRASOL Deemed Practice-Changing for Frα+ Platinum-Resistant Ovarian Cancer
Kathleen N. Moore, MD says the phase 3 MIRASOL results bring a new standard-of-care to the FRα-high, platinum-resistant ovarian cancer landscape.
Obe-cel Induces 76% CR/CRi Rate With Compelling MRD Negativity in R/R B-ALL
Phase 2 FELIX study results show 21.3% of the 94 patients infused with obecatagene autoleucel achieved a complete response or complete response with incomplete count recovery.
Simple Hysterectomy Deemed Noninferior to Radical Version in Low-Risk, Early-Stage Cervical Cancer
Canadian study results indicate surgical de-escalation is possible in patients with low-risk, early-stage cervical cancer.
Crovalimab Treatment in the COMMODORE Trial Meets Coprimary End Points
COMMODORE study results are positive for its two primary end points of stable hemolysis control and transfusion avoidance in patients with paroxysmal nocturnal hemoglobinuria treated with crovalimab.
Prior Local Treatment Does Not Impact Survival Benefit of Enzalutamide/ADT in mHSPC
Results from a post-hoc analysis of ARCHES showed that the enzalutamide plus ADT significantly improved survival, as well as key secondary end points, compared with placebo plus ADT in patients with metastatic hormone-sensitive prostate cancer.
Matched Sibling Donor Transplant Improves 2-Year Overall Survival in R/R ALL
Retrospective data signal that transplant with a matched sibling donor may prolong survival over haploidentical stem cell transplant in patients with relapsed or refractory acute myeloid leukemia.
OS of Sotorasib After Longer Follow-Up Appears Consistent for Patients With KRAS G12C+ NSCLC
Sotorasib continues to wow in the phase 1/2 CodeBreaK 100 trial of patients with KRAS G12C–mutant non–small cell lung cancer.
Adjuvant CDK4/6 Inhibitors Show Clinical Benefit in Early-Stage HR+ Breast Cancer
Results from 3 clinical trials show that adjuvant CDK4/6 inhibition is a good option for early-stage hormone-receptor-positive breast cancer.
Upfront Olaparib/Abiraterone Achieves Significant rPFS Benefit in mCRPC
A significant percentage of reduction in the risk of radiographic disease progression or death was observed with olaparib plus abiraterone compared with placebo and abiraterone in patients with metastatic castration resistant prostate cancer.
Entinostat Combined With Exemestane Extends Progression-Free Survival in Advanced HR+ BC
Phase 3 results from a cohort of patients in China show a progression-free survival benefit with entinostat/exemestane.
Elacestrant Treatment Achieves Significant PFS Improvement in Advanced ER+ Breast Cancer With or Without ESR1 Mutations
During a press briefing ahead of the 2021 San Antonio Breast Cancer Symposium, results from the phase 3 EMERALD trial were presented.
cfDNA-Based MRD Assay Is Feasible for Use in Relapsed/Refractory CLL
In patients with CLL who were treated with venetoclax, acalabrutinib, and obinutuzumab, Cell-free DNA–based minimal residual disease testing was found to be feasible.
Durvalumab Combo, With or Without Tremelimumab, Improves PFS in NSCLC
Data from the phase 3 POSEIDON trial were presented during the International Association for the Study of Lung Cancer 2021 World Conference on Lung Cancer.
Talquetamab Continues to Impress in Relapsed/ Refractory Multiple Myeloma
Findings from the phase 1 MonumenTAL-1 trial demonstrate the clinical activity of talquetamab in patients with relapsed or refractory multiple myeloma.
Nivolumab/Ipilimumab Arm Misses Mark While Nivolumab/Chemo Combo Sustains Clinical Benefit in Frontline Gastric/GEJ Cancer
The combination of nivolumab/ipilimumab did not significantly improve OS compared with chemotherapy in patients with advanced gastric, gastroesophageal junction, or esophageal cancer.
Encouraging Activity Seen With Trastuzumab Deruxtecan in Western Patients With HER2+ Gastric/GEJ Cancer
In Western patients with HER2-positive gastric/gastroesophageal junction cancer Fam-trastuzumab deruxtecan-nxki as a second-line treatment elicited a 38% confirmed objective response rate.
pCR, EFS, Improved with Neoadjuvant Carboplatin Plus Paclitaxel, Without Veliparib in TNBC
Pathological complete response rates and event-free survival in patients with treatment-naïve triple-negative breast cancer were improved with The addition of carboplatin to neoadjuvant paclitaxel followed by doxorubicin and cyclophosphamide.
DFS Benefit of Adjuvant Pembrolizumab Seen Across RCC Subgroups
An impressive disease-free survival benefit was seen in patients with clear cell renal cell carcinoma with pembrolizumab as an adjuvant therapy following nephrectomy compared with placebo. This improvement was observed across subgroups.
Checkpoint Blockade Response Linked With MSI-H/dMMR Prostate Cancer
Patients with microsatellite instability–high or mismatch repair–deficient prostate cancer may be more likely to respond to treatment with checkpoint inhibitors compared with those who have high tumor mutational burden.
Checkpoint Inhibition Plus Ablation Shows Promise in Advanced HCC
Efficacy and safety have been demonstrated with the combination of durvalumab with tremelimumab and transcatheter arterial chemoembolization or radiofrequency ablation in advanced hepatocellular carcinoma.
AMG 757 Elicits Early Response, Safety in Small Cell Lung Cancer
First-in-human results of a phase 1 trial (NCT03319940) evaluating AMG 757 in patients with small cell lung cancer revealed early signals of efficacy and a favorable safety profile in findings presented at the European Lung Cancer Virtual Congress 2021.
Delay in Initiating Durvalumab Is Shown in Real-World Study of NSCLC
The time to initiate durvalumab treatment following chemoradiation was delayed in the real-world setting trial PACIFIC-R (NCT02125461) compared with the earlier phase 3 PACIFIC trial.
Nivolumab Alone, Or With Ipilimumab Maintains Improved Outcomes in Advanced Melanoma
Looking at 6.5 years of follow-up data from the phase 3 CheckMate-067 trial shows maintained outcomes in patients with advanced melanoma on nivolumab alone, or with ipilimumab.
MAPK Expression Does not Drive Selumetinib Response in Pediatric and AYA Refractory Solid Tumors
No clinical activity was elicited by selumetinib in pediatric and young adult patients with refractory cancers.
OS improved by Frontline Avelumab Maintenance Regardless of Primary Tumor Site, Advanced Disease Type in Advanced Urothelial Cancer
Across several previously unreported subgroups of patients with advanced urothelial cancer who have progressed on first-line platinum-containing chemotherapy avelumab as frontline maintenance plus best supportive care demonstrated a survival benefit compared with BSC alone.
Adjuvant Pembrolizumab Significantly Reduces Risk of Disease Recurrence or Death in RCC
Data from the phase 3 KEYNOTE-564 trial presented in a press briefing ahead of the 2021 ASCO Annual Meeting showed that adjuvant pembrolizuumab achieved significant disease-free survival improvement compared with placebo.
AMG 716 Plus Gilteritinib Demonstrated Early Activity in FLT3-ITD+ AML
In preclinical models of acute myeloid leukemia with FLT3 internal tandem duplication mutation, AMG 176 in combination with gilteritinib demonstrated the ability to synergistically target the disease.
2 Clarke Drive Cranbury, NJ 08512